Lisa Murphy leads Avalere’s Policy 360 team, which produces business intelligence products focused on legislative and regulatory changes to the healthcare system.

Avalere Federal Policy 360­™ provides members with resources to interpret federal policy developments and insights on how policy changes impact healthcare companies. Avalere State Policy 360™ synthesizes the most important state healthcare news in a monthly publication to keep members informed about the evolving state healthcare environment.

Prior to joining Avalere in 2006, Lisa worked with the Department of Health and Human Services and the Centers for Medicare & Medicaid Services as a consultant with Booz Allen Hamilton and served as a Jacob K. Javits Policy Fellow in the Office of US Senator Jean Carnahan.

Lisa has an MPP from the Terry Sanford Institute of Public Policy at Duke University, and graduated Phi Beta Kappa with a BA in political science from the University of Richmond.

Authored Content

In plan year (PY) 2022, most states continue to rely on the federal government for some or all exchange operational functions. However, 3 states have transitioned to state-based exchanges (SBEs).

In his first address to Congress, President Biden signaled that healthcare will continue to be a high priority for his administration, specifically highlighting pandemic response, drug pricing priorities (e.g., Medicare negotiation), and Affordable Care Act (ACA) enhancements.

Healthcare stakeholders face a unique set of challenges and opportunities in 2021 as we continue to respond to the COVID-19 pandemic and prepare for the political changes inherent in a new presidential administration. As we take stock of the historic events of 2020, it is important to look ahead toward the new era already coming into view.

While the Department of Health & Human Services (HHS) did not intend for proposed changes to Anti-Kickback Statute (AKS) regulations to impact commercial market drug negotiations, some state laws may indirectly lead to commercial market implications.

Healthcare spending is expected to represent 19.4% of US GDP in 2027.

Increasingly, states are taking steps to control prescription drug spending and prices.

The number of drugs health plans are required to cover in the individual and small group markets will vary dramatically by state in 2014.